CRIS

Business Context and Reporting Period

Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: Curis, Inc. focuses on regenerative medicine and functional genomics. On July 31, 2000, the Company completed a merger with Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. Curis is the accounting successor to Creative BioMolecules, while Ontogeny and Reprogenesis were accounted for as acquisitions.

Key Financial Metrics

Material Changes vs. Prior Period

• Merger Impact: The July 31, 2000 merger with Ontogeny and Reprogenesis drove a massive increase in expenses and a corresponding net loss. The Company recorded a one-time charge of $294,800,000 for In-Process Research & Development (IPR&D) acquired in the merger.
• Revenue Decline: Research and development revenues decreased 92% to $66,000 for the quarter (from $824,000 in 1999) and 69% for the nine-month period. This was primarily due to the termination of a research agreement with Biogen, Inc. in 1999.
• Expense Surge:
  • R&D Expenses: Increased 124% for the quarter to $6.1 million, driven by the inclusion of acquired companies' costs and severance payments.
  • Stock-Based Compensation: Increased to $9.4 million for the quarter (from $0 in 1999) due to amortization of prepaid compensation from the merger and new option grants.
  • Intangible Amortization: Increased to $8.5 million for the quarter, including $3.9 million for goodwill and a $4.6 million impairment charge on capitalized patents.
• Liquidity: Cash and cash equivalents increased significantly from $2.75 million (Dec 31, 1999) to $20.6 million (Sep 30, 2000), bolstered by cash received from the acquisition ($10.8 million) and equity issuances.

Guidance, Outlook, and Risks

• Outlook: Management anticipates R&D and G&A expenses for the fourth quarter of 2000 will be slightly lower than the third quarter due to merger efficiencies and the one-time nature of severance costs. The Company plans to spend approximately $2.5 million in Q4 2000 and $6 million in 2001 on facility upgrades.
• Capital Resources: The Company expects existing capital resources to fund operations into the fourth quarter of 2001. Future funding will depend on royalties from Stryker (contingent on product approval), collaborative arrangements, or additional equity/debt financing.
• Recent Developments:
  • Received a second $2 million grant from NIST (announced Oct 5, 2000) for biomaterials development.
  • Sold restricted Exelixis, Inc. stock on Oct 9, 2000, for net proceeds of $1.995 million, realizing a loss of $1.367 million to be recorded in Q4 2000.
• Risks:
  • Profitability: No products have been commercialized; the Company expects to continue incurring substantial losses.
  • Financing: Additional financing may be required, which could dilute stockholders.
  • Merger Integration: Risks associated with integrating three distinct companies and retaining key personnel.
  • Regulatory: Dependence on FDA approvals for product commercialization.

Investor Verification Checklist

• Merger Accounting: Verify the allocation of the $449.7 million purchase price, specifically the $294.8 million IPR&D write-off and $105.5 million goodwill.
• Revenue Sustainability: Assess the impact of the terminated Biogen agreement and the reliance on NIST grants ($4 million total) versus commercial revenue.
• Stock-Based Compensation: Review the $12.5 million stock-based compensation expense for the nine months, including the amortization of prepaid compensation and deferred compensation from new option grants.
• Liquidity Runway: Confirm the $44.2 million in liquid assets (cash and marketable securities) is sufficient to cover the projected $2.5 million Q4 spend and ongoing operational losses without immediate dilution.
• Subsequent Events: Note the $1.367 million unrealized loss on Exelixis stock that will impact Q4 2000 earnings.